CLINICAL RESEARCH: ACUTE MYOCARDIAL INFARCTION
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non–ST-segment elevation acute coronary syndromes
A Fragmin and fast Revascularisation during InStability in coronary artery disease (FRISC)-II substudy
Bertil Lindahl, MD, PhD*, ,*,
Johan Lindbäck, MSc,
Tomas Jernberg, MD, PhD,
Nina Johnston, MD*,
Mats Stridsberg, MD, PhD ,
Per Venge, MD, PhD and
Lars Wallentin, MD, PhD*,
* Department of Medical Sciences and Cardiology
Department of Medical Sciences and Clinical Chemistry
Uppsala Clinical Research Center, University Hospital, Uppsala, Sweden
Manuscript received May 4, 2004;
revised manuscript received October 21, 2004,
accepted October 25, 2004.
* Reprint requests and correspondence: Dr. Bertil Lindahl, Department of Cardiology and Uppsala Clinical Research Center, University Hospital, SE-751 85 Uppsala, Sweden (Email: bertil.lindahl{at}akademiska.se).
OBJECTIVES: The aim of this research was to describe N-terminal part of the pro-B-type natriuretic peptide (NT-proBNP) levels over time in non–ST-segment elevation acute coronary syndromes (NSTEACS), to elucidate factors associated with changes of NT-proBNP levels, and to examine association with long-term mortality.
BACKGROUND: The NT-proBNP levels are associated with mortality. Long-term temporal changes of NT-proBNP levels and their relation to other factors have not been examined.
METHODS: The NT-proBNP was analyzed at randomization and at 48 h, after 6 weeks, 3 and 6 months in NSTEACS patients enrolled in the Fragmin and fast Revascularisation during InStability in Coronary artery disease (FRISC)-II trial. The NT-proB-type natriuretic peptide was analyzed at least three time points in 1,216 patients.
RESULTS: The median NT-proBNP level, which at randomization was 529 ng/l, decreased throughout the whole sampling period to 238 ng/l at six months. Elevated troponin T, C-reactive protein, and female gender were associated with higher reduction rates, and high age, diabetes, previous myocardial infarction, treatment with diuretics, and nitrates on admission with lower reduction rates. At each time point, the NT-proBNP level was predictive of the two-year mortality. However, the adjusted odds ratio increased for each time point.
CONCLUSIONS: The initial rise of NT-proBNP in NSTEACS is mainly reversible. Factors associated with less reversibility are related to chronically impaired left ventricular function, and factors associated with greater reversibility are related to the acute myocardial damage. The NT-proBNP level measured during a chronic, relatively stable phase is a better predictor of mortality than during an acute unstable phase. The clinical setting and timing of measurement will be important to consider when using NT-proBNP for risk assessment.
|
Abbreviations and Acronyms
| | BNP = B-type natriuretic peptide | | CHF = congestive heart failure | | CRP = C-reactive protein | | cTnT = cardiac troponin T | | FRISC-II = Fragmin and fast Revascularisation during InStability in Coronary artery disease trial | | LVEF = left ventricular ejection fraction | | MI = myocardial infarction | | NSTEACS = non–ST-segment elevation acute coronary syndrome | | NT-proBNP = N-terminal part of the pro-B-type natriuretic peptide |
|
This article has been cited by other articles:
|
|
|
|
 
P. R. Sinnaeve, J. A. Ezekowitz, K. Bogaerts, W. Droogne, R. Jarai, K. Huber, C. B. Granger, W. J. Desmet, P. W. Armstrong, F. J. Van de Werf, et al.
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis
Eur. Heart J.,
September 2, 2009;
30(18):
2213 - 2219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Eggers, B. Lagerqvist, P. Venge, L. Wallentin, and B. Lindahl
Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome.
J. Am. Coll. Cardiol.,
July 21, 2009;
54(4):
357 - 364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. deFilippi and S. L. Seliger
Biomarkers for prognostication after acute coronary syndromes: new times and statistics.
J. Am. Coll. Cardiol.,
July 21, 2009;
54(4):
365 - 367.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zeller, P. G. Steg, J. Ravisy, L. Lorgis, Y. Laurent, P. Sicard, L. Janin-Manificat, J.-C. Beer, H. Makki, A.-C. Lagrost, et al.
Relation Between Body Mass Index, Waist Circumference, and Death After Acute Myocardial Infarction
Circulation,
July 29, 2008;
118(5):
482 - 490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Morrow, M. S. Sabatine, M.-L. Brennan, J. A. de Lemos, S. A. Murphy, C. T. Ruff, N. Rifai, C. P. Cannon, and S. L. Hazen
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18
Eur. Heart J.,
May 1, 2008;
29(9):
1096 - 1102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.C. Astor, S. Yi, L. Hiremath, T. Corbin, V. Pogue, B. Wilkening, G. Peterson, J. Lewis, J.P. Lash, F. Van Lente, et al.
N-Terminal Prohormone Brain Natriuretic Peptide as a Predictor of Cardiovascular Disease and Mortality in Blacks With Hypertensive Kidney Disease: The African American Study of Kidney Disease and Hypertension (AASK)
Circulation,
April 1, 2008;
117(13):
1685 - 1692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M G Nicholls, C M Frampton, and T G Yandle
BNP: not just for heart failure
Heart,
January 1, 2008;
94(1):
6 - 7.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Daniels and A. S. Maisel
Natriuretic Peptides
J. Am. Coll. Cardiol.,
December 18, 2007;
50(25):
2357 - 2368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Wollert, T. Kempf, B. Lagerqvist, B. Lindahl, S. Olofsson, T. Allhoff, T. Peter, A. Siegbahn, P. Venge, H. Drexler, et al.
Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non ST-Elevation Acute Coronary Syndrome
Circulation,
October 2, 2007;
116(14):
1540 - 1548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
Circulation,
July 31, 2007;
116(5):
e99 - e109.
[Full Text]
[PDF]
|
|
|
|
|
|
|
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
Circulation,
April 3, 2007;
115(13):
e356 - e375.
[Full Text]
[PDF]
|
|
|
|
|
|
|
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
Clin. Chem.,
April 1, 2007;
53(4):
552 - 574.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Morrow, J. A. de Lemos, M. A. Blazing, M. S. Sabatine, S. A. Murphy, P. Jarolim, H. D. White, K. A. A. Fox, R. M. Califf, E. Braunwald, et al.
Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients With Unstable Coronary Artery Disease
JAMA,
December 14, 2005;
294(22):
2866 - 2871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mockel, R. Muller, J. O. Vollert, C. Muller, A. Carl, D. Peetz, F. Post, J. K. Kohse, and K. J. Lackner
Role of N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification in Patients Presenting in the Emergency Room
Clin. Chem.,
September 1, 2005;
51(9):
1624 - 1631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
